MET and pancreatic neoplasm: Its clinical relevance to pancreatic cancer has also been demonstrated, with various studies reporting on the overexpression of MET in pancreatic cancers [40] and a correlation between elevated serum levels of HGF and aggressive PDAC phenotypes [41].